• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
NMS-1286937

NMS-1286937

Product ID N5072
Cas No. 1034616-18-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $142.80 In stock
5 mg $228.10 In stock
10 mg $346.10 Please Inquire
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

NMS-1286937 is an inhibitor of polo-like kinase 1 (PLK1) that is currently in clinical trials as a potential treatment for various cancers; it exhibits anticancer chemotherapeutic activity. In osteosarcoma cells, NMS-1286937 induces cell cycle arrest and apoptosis and inhibits cell growth. In animal models of acute myelogenous leukemia (AML), this compound increases survival time and decreases tumor cell infiltration. Additionally, NMS-1286937 inhibits cell proliferation and induces apoptosis, cell cycle arrest, and tumor regression in cellular and animal models of colon cancer.

Product Info

Cas No.

1034616-18-6

Purity

≥98%

Formula

C24H27F3N8O3

Formula Wt.

532.52

IUPAC Name

1-(2-Hydroxyethyl)-8-{[5-(4-methyl-1-piperazinyl)-2-(trifluoromethoxy)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide

Synonym

NMS1286937, NMS-P937

Solubility

DMSO 42 mg/mL warmed (78.87 mM) Ethanol 10 mg/mL warmed (18.77 mM) Water Insoluble

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

N5072 MSDS PDF

Info Sheet

N5072 Info Sheet PDF

References

Sero V, Tavanti E, Vella S, et al. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs. 2014 Dec;32(6):1167-80. PMID: 25193492.

Casolaro A, Golay J, Albanese C, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8(3):e58424. PMID: 23520509.

Valsasina B, Beria I, Alli C, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11(4):1006-16. PMID: 22319201.

Beria I, Bossi RT, Brasca MG, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74. PMID: 21470862.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • O1179

    n-Octyl-4-methylcaffeate

    Derivative of methyl caffeate, hydroxycinnamic ...

    ≥98%
  • W2800

    WH-4-023

    Lck, Src, SIK inhibitor.

    ≥99 %
  • A4849

    Amyloid-β (25-35)

    Endogenous APP peptide cleavage product, primar...

    ≥95%
  • A1218

    Adefovir Dipivoxil

    Acyclic nucleotide (adenosine) analog, adefovir...

    ≥98%
  • C0156

    9-Nitro-20S-camptothecin

    Camptothecin derivative; topoisomerase I inhibi...

    ≥98%
  • J291331

    JH-II-127

    Selective inhibitor of LRRK2.

    ≥98%
  • L0362

    Lapatinib free base

    Inhibitor of EGFR/HER2 (ErbB2).

    ≥99%
  • D3349

    Dimebon Dihydrochloride

    AMPK activator, L-type Ca2+ channel and NMDA, h...

    ≥98%
  • B7058

    Brompheniramine Maleate

    Pheniramine derivative; histamine H1 and mAChR ...

    ≥98%
  • H1658

    Heparin Sodium

    Endogenous glycosaminoglycan that is produced b...

    Bioassay ≥140 U/mg
  • E537335

    Enniatin B1

    Mycotoxin contaminant found in cereal grains.

    ≥98%
  • L1869

    Lercanidipine Hydrochloride

    Calcium channel blocker.

    ≥98%
  • C0168

    Canthaxanthin

    Carotenoid terpene pigment found in various plant ...
    ≥9% (product contains stabilizers)
  • K624760

    KPT-276

    CRM1/XPO1 inhibitor.

    ≥99%
  • N1976

    Netilmicin Sulfate

    Aminoglycoside; protein translation inhibitor.<...

    ≥98%
  • C0246

    Calcimycin

    Polyether pyrrole, divalent cation ionophore.

    ≥98%
  • M3377

    Mitomycin C

    Alkaloid produced by Streptomyces, DNA cross-li...

    ≥98%
  • L960006

    LY-2606368

    CHK1 inhibitor.

    ≥98%
  • A1333

    Adipokinetic Hormone II from Schistocera gregaria

    Neuropeptide found in Schistocera gregaria.

    ≥95%
  • P0278

    Patulin

    Mycotoxin produced by Penicillum and Aspergillu...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only